Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | ICMT | O60725 | 5/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30886441 | 0.87 | HDAC1 (0.35) | DGAT1ICMTHDAC1HTTKIF11 | |
| SCHEMBL24575335 | 0.86 | KDM1A (0.38) | DGAT1ICMTHDAC1HDAC8HTT | |
| SCHEMBL3366555 | 0.82 | CXCL8 (0.40) | HDAC1HDAC8 | |
| SCHEMBL30835160 | 0.82 | CXCL8 (0.40) | HDAC1HDAC8 | |
| SCHEMBL29819673 | 0.81 | HDAC1 (0.40) | ICMTHDAC1HDAC8HTTRORC | |
| SCHEMBL12984764 | 0.81 | HDAC1 (0.40) | ICMTHDAC1HDAC8HTTRORC | |
| SCHEMBL30886478 | 0.80 | MEN1 (0.38) | HTT | |
| SCHEMBL31485520 | 0.79 | CCR6 (0.36) | DGAT1ICMTRORCCA2CA12 | |
| SCHEMBL30886492 | 0.79 | KIF11 (0.34) | DGAT1ICMTHDAC1HTTKIF11 | |
| SCHEMBL4314806 | 0.78 | KIF11 (0.36) | DGAT1ICMTHDAC1HDAC8HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160137633-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING DIABETES | AJINOMOTO CO., INC. (JP) | 2016-05-19 | — | — | US | disclosed |
| US-9290487-B2 | Pharmaceutical composition for treating diabetes | AJINOMOTO CO., INC. (JP) | 2016-03-22 | — | — | US | disclosed |
| US-20140336376-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING DIABETES | AJINOMOTO CO., INC. (JP) | 2014-11-13 | — | — | US | disclosed |
| EP-2774917-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING DIABETES | Ajinomoto Co., Inc. (JP) | 2014-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336376-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING DIABETES | PPARG, GPR119, GYS2 | DGAT1 184/4885ICMT 4450/4885HDAC1 911/4885 |
| US-20160137633-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING DIABETES | PPARG, GPR119, GYS2 | DGAT1 184/4885ICMT 4450/4885HDAC1 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.